CDK7-IN-30 

CDK7-IN-30 (Compound 22) is a CDK7 inhibitor (IC₅₀ = 7.21 nM) that effectively inhibits the phosphorylation of RNA Polymerase II and CDK2. CDK7-IN-30 CDK7-IN-30 can induce cell apoptosis and has anti-cancer activity and can be used in cancer research^[1].

CDK7-IN-30 (Compound 22) demonstrates potent antiproliferative effects on cancer cells, with IC₅₀ values of 288.0 nM (RS4;11), 174.6 nM (MM.1S), 37.5 nM (Mino), and 168.7 nM (Jeko-1), respectively. Meanwhile, CDK7-IN-30 exhibits weaker inhibitory effects on normal blood cells PBMCs, with an IC₅₀ value of 757.9 nM^[1].
CDK7-IN-30 (50-500 nM; 24 h) causes cell cycle arrest in G1/S phase and (100-1000 nM; 48 h) promotes apoptosis in MV4-11 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

466.00

C₂₁H₂₈ClN₅O₃S

3040999-70-7

CC(C)S(C(C=CC=C1)=C1NC2=NC(N[C@@H]3CC[C@H](CC3)NC(C)=O)=NC=C2Cl)(=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Zhang H, et al. Design, Synthesis, and Biological Evaluation of 2, 4-Diaminopyrimidine Derivatives as Potent CDK7 Inhibitors[J]. ACS Medicinal Chemistry Letters, 2024.